<DOC>
	<DOC>NCT00119600</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 114 administered subcutaneously for the treatment of chemotherapy induced anemia in subjects receiving multicycle chemotherapy.</brief_summary>
	<brief_title>A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Part A: Nonmyeloid malignancy receiving multicycle chemotherapy Receiving nonplatinum containing chemotherapy At least 6 additional weeks of cyclic cytotoxic chemotherapy planned Part B and Part C: Nonmyeloid malignancy receiving multicycle chemotherapy At least 12 additional weeks of cyclic cytotoxic chemotherapy planned All Parts: Chemotherapy induced anemia Greater than 6 month life expectancy ECOG 02 Adequate renal and liver function Chronic myeloid leukemia, AML, ALL, Burkitt's lymphoma or lymphoblastic lymphoma History of seizure disorder Primary hematologic disorder which could cause anemia, other than a nonmyeloid malignancy Unstable angina, congestive heart failure or uncontrolled cardiac arrhythmia Uncontrolled hypertension History of pure red cell aplasia Clinically significant inflammatory disease or active infection Iron deficiency ANC less than 0.8 x 10^9 cells/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>